Last reviewed · How we verify
NCT00898495
Genes in Predicting Outcome in Patients With Esophageal Cancer Treated With Cisplatin, Radiation Therapy, and Surgery
trial testing loss of heterozygosity analysis in Esophageal Cancer in 118 participants. Completed in 31 December 2008.
31 December 2008
Quick facts
| Lead sponsor | ECOG-ACRIN Cancer Research Group |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 118 |
| Start date | 11 May 2007 |
| Primary completion | 31 December 2008 |
| Estimated completion | 31 December 2008 |
Drugs / interventions tested
- loss of heterozygosity analysis
- polymerase chain reaction
- polymorphism analysis
Conditions studied
- Esophageal Cancer — all drugs for Esophageal Cancer →
Sponsor
ECOG-ACRIN Cancer Research Group
Who can join
Adults 18 to 120, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Studying samples of tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict a patient's response to treatment. PURPOSE: This laboratory study is looking at genes to see if they can predict outcome in patients with esophageal cancer treated with cisplatin, radiation therapy, and surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00898495
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of loss of heterozygosity analysis
Trials testing the same drug.
- NCT00897819 — Studying DNA and Outcome in Patients With Advanced Colorectal Cancer Treated With Fluorouracil and Oxaliplatin With or W · completed
Other recruiting trials for Esophageal Cancer
Currently open trials in the same condition.
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting
Other ECOG-ACRIN Cancer Research Group trials
Trials by the same sponsor.
- NCT07001748 — Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With G · Phase 2, PHASE3 · recruiting
- NCT06526897 — Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Ext · NA · not yet recruiting
- NCT06475989 — Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer · Phase 3 · recruiting
- NCT06084845 — Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for P · Phase 2 · withdrawn
- NCT06319027 — Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Tr · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00898495 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ECOG-ACRIN Cancer Research Group
- Last refreshed: 31 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00898495.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing